Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-31
2011-05-31
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S575000
Reexamination Certificate
active
07951797
ABSTRACT:
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
REFERENCES:
patent: 6838465 (2005-01-01), Yamada et al.
patent: 2006/0258672 (2006-11-01), Barbosa et al.
patent: 2009/0192143 (2009-07-01), Cox et al.
patent: 2010/0256121 (2010-10-01), Bergman et al.
patent: 0794178 (1995-09-01), None
patent: WO 00/47576 (2000-08-01), None
patent: WO 01/68609 (2001-09-01), None
patent: WO 01/96302 (2001-12-01), None
patent: WO 02/89800 (2002-05-01), None
patent: WO 02/44172 (2002-06-01), None
patent: WO 02/051838 (2002-07-01), None
patent: WO 02/090355 (2002-11-01), None
patent: WO 03/002559 (2003-01-01), None
patent: WO 03/002561 (2003-01-01), None
patent: WO 03/032991 (2003-04-01), None
patent: WO 03/037847 (2003-05-01), None
patent: WO 03/041711 (2003-05-01), None
patent: WO 03/051368 (2003-06-01), None
patent: WO 03/051873 (2003-06-01), None
patent: WO 2004/004733 (2004-01-01), None
patent: WO 2004/026866 (2004-04-01), None
patent: WO 2004/041816 (2004-05-01), None
patent: WO 2004080976 (2004-09-01), None
patent: WO 2004/085403 (2004-10-01), None
patent: WO 2004/096780 (2004-11-01), None
patent: WO 2005023261 (2005-03-01), None
patent: WO 2005/075458 (2005-08-01), None
patent: WO 2005/118548 (2005-12-01), None
patent: WO 2006/067224 (2006-06-01), None
patent: WO 2006/127550 (2006-11-01), None
patent: WO 2007/025069 (2007-03-01), None
patent: WO 2007/126935 (2007-11-01), None
patent: WO 2008008517 (2008-01-01), None
patent: WO 2008008518 (2008-01-01), None
patent: WO 2008069997 (2008-06-01), None
patent: WO 2009058238 (2009-05-01), None
Cai, et al., Expert Opn.Ther. Patents, (2006) 16(5), 631-646.
Coleman et al., Bioorg. Med. Chem. Lett., (2010) 20, 2311-2315.
Coleman et al., Expert Opn. Ther. Patents, (2010) 20(3), 307-324.
Coleman et al., “Discovery of MK-4305: A Novel Orexin Receptor Antagonist for the Treatment of Insomnia”, Presentation at American Chemical Society 239th National Meeting and Exposition, San Francisco, CA Mar. 12-25, 2010.
Coleman et al., “Discovery of a Novel Orexin Receptor Antagonist for the Treatment of Sleep Disorders”, Presentation at 21st Int'l Symposium on Medicinal Chemistry, Brussels, Belgium Sep. 5-9, 2010.
Cox, et al., J. Med. Chem., (2010) 53, 5320-5332.
Cox et al., “Discovery of potent, CNS-penetrant dual orexin receptor antagonists containing a 1,4-diazepan central constraint that promotes sleep in rats”, Presentation at the 228th National ACS Meeting, Washington, DC Aug. 20, 2009.
Herring, et al., “MK-4305 Dual Orexin Receptor Antagonist (DORA) Phase IIB Study in Primary Insomnia”, Ass'n of Professional Sleep Societies 24th Annual Meeting, San Antonio, Texas Jun. 5-10, 2010.
Sun, et al., “Effects of MK-4305, a Dual Orexin Receptor Antagonist, on Sleep Parameters as Measured by PSG in Healthy Male Subjects”, Ass'n of Professional Sleep Societies 24th Annual Meeting, San Antonio, Texas Jun. 5-10, 2010.
Roecker, et al., Current Topics in Med. Chem., (2008), 8, 977-987.
Roecker et al., “Discovery of Potent, Diazepan-containing Dual Orexin Receptor Antagonists for the Treatment of Insomnia”, Presentation at the 28th Camerino-Cyprus-Noordwijkerhout Symposium, Camerino Italy, May 19, 2010.
Whitman, et al., ChemMedChem (2009), 4, 1069-1074.
WO 2008/069997, International Preliminary Report on Patentability, Jun. 3, 2009.
EP 07862400, Communication from EPO, Aug. 24, 2009.
EP 07862400, Response submitted to EPO, Mar. 1, 2010.
Breslin Michael J.
Coleman Paul J.
Cox Christopher D.
Coleman Brenda L
Devlin Gerard M.
Merck Sharp & Dohme Corp.
Thies J. Eric
LandOfFree
Substituted diazepan orexin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diazepan orexin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diazepan orexin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628887